Hla class ii-restricted tcrs against the kras g12>v activating mutation

The method of claim 27, wherein contacting is further defined as transfecting or transducing, wherein transfecting comprises electroporating RNA encoding the TCR of any one of claims 1-8 into the immune cell.

A method for treating a subject with a cancer comprising a KRAS G12>V mutation peptide, the method comprising:

• administering to the subject an effective amount of one or more immune cells modified by cloning genes of the alpha and beta chains of a T cell receptor (TCR) ex vivo to express a chimeric antigen receptor specific for the KRAS G12>V mutation, wherein the chimeric antigen receptor comprises an alpha chain CDR3 having the amino acid sequence of SEQ ID NO:
• 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 and/or a beta chain CDR3 having the amino acid sequence of SEQ ID NO:
• 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24.

A chimeric antigen receptor expressing T cell (CAR-T) comprising an antigen recognition moiety and a T-cell activation moiety, wherein the T-cell activation moiety comprises a transmembrane domain, and wherein the antigen recognition moiety is directed against a KRAS G12>V mutation.